Evotec SE (EVO) Fair Value 2026

EVO · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.2 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-28, Evotec SE (EVO) trades at $1.91. QOC: 6.2/10. Value Trap Risk: 26/100 (LOW). 1/13 models active.

Key Facts

Ticker
EVO
Price
$1.91
Quality Score
6.2/10
Value Trap Risk
26/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +151.9% upside with 21% confidence
Risk: Limited model coverage (1/13) may reduce confidence

What Fair Value Does Each Model Give EVO?

1 Intrinsic Value Models vs. Current Price ($1.91)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $4.81 +151.9%

All Models Active

All 1 models are displayed above.

What Is Evotec SE (EVO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Evotec SE. Trading at $1.91 against an estimated intrinsic value of $4.81, 1 of 1 active models flag meaningful upside of +151.9% at the median.

What Do the Models Say About EVO?

1 of 13 models are currently active for EVO. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does EVO Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, EVO ranks #48 by Quality of Company score. CirclFi's QOC score of 6.2/10 evaluates 32 fundamental signals. A score of 6.2 indicates above-average quality.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

Evotec SE's positioning within the Drug Manufacturers - Specialty & Generic segment means that R&D productivity ratio plays an outsized role in fundamental analysis. The sector's unique characteristics — including regulatory pathway clarity — shape both the opportunity set and risk profile.

Is EVO a Value Trap?

CirclFi's Value Trap algorithm assigns EVO a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Evotec SE. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Evotec SE scores 6.2 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every EVO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across EVO's 1 active models, average confidence is 21%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Evotec SE Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

DERMJourney Medical CorporationQOC 6.2EOLSEvolus, Inc.QOC 6.2TXMDTherapeuticsMD, Inc.QOC 6.2SCYXSCYNEXIS, Inc.QOC 6.1ZYBTZhengye Biotechnology Holding LimitedQOC 6.2AYTUAytu BioPharma, Inc.QOC 6.1AMLXAmylyx Pharmaceuticals, Inc.QOC 5.1GREHGreen Rain Energy Holdings Inc.QOC 3.3XERSXeris Biopharma Holdings, Inc.QOC 7.9UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: DERM · EOLS · TXMD · SCYX · ZYBT · AYTU · AMLX · GREH · XERS · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to EVO?

7 companies across all industries closest to EVO’s Quality of Company score of 6.2/10.

GLDGGoldMining Inc.QOC 6.2GRALGRAIL, Inc.QOC 6.2CLDXCelldex Therapeutics, Inc.QOC 6.2DTILPrecision BioSciences, Inc.QOC 6.2GETYGetty Images Holdings, Inc.QOC 6.2PPHCPublic Policy Holding Company, Inc.QOC 6.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GLDG · GRAL · CLDX · DTIL · GETY · PPHC · NVDA

Where Does EVO Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

EVO is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Evotec SE’s Valuation?

What is Evotec SE's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Evotec SE (EVO). The Quality of Company score is 6.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is EVO overvalued or undervalued right now?

At $1.91, 1 of 1 active models suggest EVO may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Evotec SE's business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 6.2 mean for EVO?

Evotec SE's QOC of 6.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on EVO?

CirclFi analyzes EVO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is EVO a value trap in 2026?

Evotec SE's Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Evotec SE (EVO) a Quality of Company score of 6.2/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/EVO/ · Methodology
Primary sources for this EVO valuation
  • Financial statements: Evotec SE 10-K and 10-Q filings on SEC EDGAR (CIK 0001412558) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for EVO as of ; valuations recomputed .